

Breast cancer diagnosis and staging in Chile: A non-randomized survey-based study to assess frequency and delays

Carla Campaña^{a, b} , Marcela Oyarte^{c*} , Báltica Cabieses^{a, b, d} , Alexandra Obach^{a, b, d} 

^aCentro de Salud Global Intercultural, Facultad de Medicina-Clínica Alemana, Universidad del Desarrollo, Santiago, Chile; ^bFacultad de Psicología, Universidad del Desarrollo, Santiago, Chile; ^cSubdepartamento Innovación y Desarrollo y Departamento Agencia Nacional de Dispositivos Médicos, Innovación y Desarrollo, Instituto de Salud Pública de Chile, Santiago, Chile; ^dCentro para la Prevención y Control del Cáncer, Santiago, Chile

ABSTRACT

INTRODUCTION Breast cancer progression involves physiological mechanisms such as metastasis. Delays in diagnosis and treatment increase the risk of mortality and are associated with barriers to healthcare access. In Chile, breast cancer is highly prevalent, and early diagnosis has improved, although disparities in the disease evolution persist. This study characterized diagnostic and staging tests, waiting times, and sociodemographic profiles to identify delays and inequities in care.

METHODS Survey study. Using a non-probabilistic sample, a questionnaire was applied in an encrypted platform with prior informed consent. The instrument collected data on requested tests, associated times, staging, and sociodemographic characteristics. These variables were analyzed using descriptive statistics, tests of association, confidence intervals, and comparison tests using bootstrapping.

RESULTS A sample of 263 persons was obtained. The most requested tests were biopsy (99.62%) and blood tests (80.23%). The median number of tests requested was six (Q1:4, Q3:8), with a mean of 5.87 (standard deviation: 2.24). No significant differences were observed in the percentage of persons from whom the total number of examinations were requested according to the studied variables. The day-hour-result intervals ranged from 1 to 365 days. The median day-hour-result of the biopsy was 15 days (Q1:10, Q3:30). People between 40 and 49 years old, non-residents of the capital city, belonging to income quintile I, with high school education, from the public health system, with late-stage diagnosis had higher median day-hour-result in biopsy. There was no significant difference in the number of requested tests according to staging (I and II, or III and IV).

CONCLUSIONS Biopsy in Chile is the test of choice for diagnostic confirmation in breast cancer. Other tests are requested regardless of the diagnosis stage, contrary to the recommendations of clinical guidelines. Cancer prognosis is crucial, especially in countries with greater inequalities.

KEYWORDS Breast Neoplasms, diagnosis, Time-to-Treatment, Early Detection of Cancer, social determinants of health, biopsy, Health Inequities

INTRODUCTION

The progression of breast cancer includes specific physiological mechanisms such as metastatic capacity, increased angiogenesis, evasion of apoptosis, and unlimited cell

divisions, among others [1], and there is a continuous search for new prognostic biomarkers for clinical management and improved outcomes of care [2]. Although the physiological contribution to the prognosis of breast cancer is indisputable, it is relevant to consider the impact of cancer in different population groups and in low- and middle-income countries with greater inequalities and vulnerable populations [3,4]. In turn, it is important to recognize that access to timely diagnosis and treatment is fundamental to improving healthcare outcomes for patients with cancer [2].

Diagnostic and treatment delays in breast cancer have been associated with an increased mortality risk [5–9]. These

* Corresponding author moyarte@ispch.cl

Citation Campaña C, Oyarte M, Cabieses B, Obach A. Breast cancer diagnosis and staging in Chile: A non-randomized survey-based study to assess frequency and delays. *Medwave* 2024;24(9):e2801

DOI 10.5867/medwave.2024.09.2801

Submitted Nov 22, 2023, **Accepted** Jul 26, 2024,

Published Oct 14, 2024

Postal address Marathon 1000, Ñuñoa, Santiago, Chile

MAIN MESSAGES

- Breast cancer is a global problem, and Chile faces challenges in its diagnosis and treatment. Diagnostic delays are related to access barriers and socioeconomic factors.
- This research is novel because it addresses the management of breast cancer examinations in Chile from the viewpoint and experience of the users of the healthcare system.
- The results showed that multiple tests were requested regardless of the cancer stage (I to II, III to IV), with biopsy being the most requested and most delayed test.
- This study's limitations are the research design and sample size, which did not allow for establishing causal relationships.

delays may be related to healthcare access barriers [10]. Such barriers mainly affect low- and middle-income countries [11] and populations living at socioeconomic disadvantage [12–16]. The literature does not identify a universal consensus on diagnostic and treatment intervals for better prognosis [11,17] in breast cancer. However, a reported interval to identify delays in this neoplasm consists of more than three months between detecting symptoms and initiating treatment [10,17–20].

Breast cancer is a global healthcare concern. In 2020, it was the most diagnosed cancer in the world, with 2.2 million cases, according to the World Health Organization [21]. In Latin America, this was the most frequent cancer in women [22], and in recent decades, there has been an increasing trend in mortality [23]. Chile ranks sixth in breast cancer incidence in Latin America [22]. Data obtained from the Global Cancer Observatory show that breast cancer is the second most common cancer in the country, with an age-adjusted rate of 17.7 per 100 000 inhabitants [24] and a mortality rate of 10.2 per 100 000 inhabitants [24]. According to the Department of Information and Statistics of the Ministry of Health, the adjusted mortality rate of this cancer between 1990 and 2015 was 12.9 women died per 100 000 inhabitants [25].

In Chile, when analyzing cancer mortality from the social determinants of health approach, the main disparities are demographic (sex, age, place of residence), socioeconomic (education, household income), and healthcare system (type of health insurance) [12–16]. In breast cancer, national studies have identified differences in mortality according to place of residence (region, urban, rural) [26] and educational level [27]. To address these differences, in 2005, breast cancer was included in the plan of Explicit Health Guarantees (GES) [28]. One of the universal guarantees of this plan in breast cancer establishes that the interval between suspicion and diagnosis should not exceed 45 days. Likewise, the interval between diagnosis and staging should not exceed 45 days. In addition, the clinical guidelines for this cancer provide recommendations related to diagnostic confirmation and staging tests [28]. For diagnostic confirmation, the recommended test is percutaneous breast biopsy. In addition, other complementary tests are not recommended in asymptomatic stage I and II patients. For staging and extension studies in patients with suspected systemic involvement, chest radiography and/or computed axial tomography of the chest, ultrasound of the abdomen-pelvis

and/or computed axial tomography of the abdomen-pelvis, bone scintigraphy, and magnetic resonance imaging are recommended. The management of hours, execution, and obtaining the results of these exams represent the patient's navigation in the system, ideally with the support of the treating team. These times are critical to achieving compliance with the Plan of Explicit Health Guarantees in breast cancer.

Data from Chile in recent years have shown an increase in breast cancer diagnoses in early stages (In Situ, I and II), a trend towards an increase in stage IIA diagnoses [29], and a reduction in stage IV [28]. However, differences persist between groups of women according to socioeconomic level, type of insurance, and region of residence [12–16].

Currently, in Chile, there is no detailed research on the patients' experience concerning access to diagnostic and staging for breast cancer in Chile. Nevertheless, this is an essential and indispensable process for diagnosis and treatment selection, representing a gap to be considered. Studying this problem could allow us to identify whether there are delays in the diagnostic and staging processes, as well as to explore inequities associated with specific characteristics when stratifying by clinical (staging), sociodemographic (age, sex, region of residence, educational level, household income) and health system (type of healthcare system) determinants. Considering the above, this research aimed to characterize the profile of breast cancer diagnostic and staging examinations in Chile in terms of requested exams, time intervals between requesting the exam and getting time to perform them and the delivery of results, and the sociodemographic profile of the participant.

METHODS**Design**

A retrospective, cross-sectional, retrospective, quantitative, retrospective survey nested in a multimethod study of therapeutic trajectories of breast cancer experience in the Chilean health system. This work was conducted between 2021 and 2022 [30]. From the research conducted in 2022 by Cabieses, Obach, Espinoza, and Rodriguez, the samples related to breast cancer for this study were extracted, as well as the databases of the variables of interest for the stated objective. The characteristics and results of this study are available in the

institutional repository of the Universidad del Desarrollo with open-access [30].

Sample

The target population was adults who reported to be living or to have lived with breast cancer at the time of answering the survey. In addition, they had to have received healthcare services in public or private facilities (hospitals, private clinics, primary care centers, etc.) of the Chilean healthcare system.

A sample was drawn from the target population based on a non-probabilistic sampling design (convenience sampling allows selecting those accessible cases that agree to be included based on convenience or proximity). For this purpose, participants were recruited through contact networks generated through permanent links with healthcare services, public and private healthcare teams, and organized groups of cancer-related patients nationwide. These contact networks informed people about the profile of the study's target population. For this purpose, an informative poster providing the contact details of the study coordinator was handed out, with whom they could directly answer the questionnaire via telephone or WhatsApp. They could also enter directly to answer the questionnaire via QR code. Additionally, to expand the sample, dissemination posters were created for social networks, open seminars, radio and press appearances, and emails inviting participation that included the link to the online survey.

Upon entering the survey on the encrypted Alchemer platform, there were rigorous questions to check the inclusion criteria for all participants. The inclusion criteria were:

1. To have lived or to be living with breast cancer.
2. To be 18 years of age or older.
3. To be treated in Chile's public or private healthcare system.
4. Have access to the Internet (personal or through the survey coordinator) or a telephone call to answer the survey.
5. Have the cognitive abilities to understand and respond to the survey questions.

The recruitment process (between August 2021 and April 2022, both months included), according to the study's timeframe.

Survey and data collection

The measurement instrument was a structured questionnaire designed by the research team based on a scoping review of international literature and according to the guidelines of the Chilean clinical guide. The instrument was previously piloted and included the following dimensions:

1. Demographic and socioeconomic profile and working conditions.
2. Medical history.
3. Forecast and perception of the healthcare system.

4. Therapeutic trajectory according to the flow of care.
5. Quality of care and overall satisfaction.

At the end of the nine-month recruitment period (August 2021 and April 2022, both months included), the participants' responses could be downloaded directly to the Alchemer platform in Excel format.

According to clinical guidelines [28], the questionnaire considered estrogen receptor, progesterone receptor, HER2, and Ki67 for tumor marker tests, confirmation, and staging for biopsy. To study the extension, chest X-ray and/or computed axial tomography, abdominal and pelvic ultrasound and/or computed axial tomography, bone scintigraphy, and resonance imaging were considered.

Study variables

Primary variables

1. Request for tests: through the question "What tests were requested to study the stage of your disease?" a series of tests were listed (biopsy, tumor marker tests according to clinical guidelines: estrogen receptor, progesterone receptor, HER2 and Ki67, computed axial tomography or chest scan, abdomen-pelvis ultrasound, abdomen-pelvis computed axial tomography, bone scintigram, magnetic resonance imaging, chest x-ray and positron emission tomography), indicating whether it was requested, not requested or does not know.
2. Days elapsed: the number of days elapsed between the request and the receipt of the results of each examination was consulted.
3. Examination perceived to have taken the longest: from the list of nine examinations, "Which test took the longest to complete?" was asked, and only one could be selected.

Secondary variables

The following were considered as secondary variables:

1. Sex (male, female).
2. Age (continuous and categorized as from 40 years, from 40 to 49, from 50 to 69, and from 70 to 83 years, according to the Chilean breast cancer clinical guidelines [28] and the recommendations of the American Cancer Society [31]).
3. Region of residence (Metropolitan region or other).
4. Monthly income (continuous and according to quintile).
5. Educational level (elementary, middle, high school, higher).
6. Health insurance (public, private system).
7. Complementary health insurance (have, don't have).
8. Breast cancer staging (stage II to II, stage III to IV, according to the screening recommendation of breast cancer clinical guidelines for patients over 15 years of age [28]).

The category “no response or unknown” was included in all cases.

The sociodemographic variables, type of tests requested, staging, and tests with the longest perceived delay correspond to qualitative variables. Meanwhile, the number of examinations and the delay between requesting them, the moment of performing them, and obtaining the results correspond to quantitative variables.

Statistical analysis

The following indicators were constructed based on the variables for requesting examinations:

1. Number of requested examinations (from 1 to 9).
2. Combination of requested exams.
3. Total number of requested exams.

These indicators, together with the rest of the variables, were analyzed descriptively using measures of frequency, central tendency, position, and dispersion according to the nature of the variable. The distribution type of continuous variables was assessed using the Kolmogorov-Smirnov normality test with Lilliefors correction. In addition, both the indicators constructed and the primary variables were described according to sociodemographic, economic, health insurance, complementary insurance, and cancer staging characteristics (secondary variables). All estimated percentages were accompanied by their respective confidence intervals. Regarding the sampling, confidence intervals were constructed using Bootstrap for a proportion [32]. Based on the resampling method (using 100 000 replicates), the success proportions were calculated, and the confidence interval was constructed using the corresponding Bootstrap distribution's percentiles to determine the confidence interval's upper and lower bounds.

Differences between the proportion of respondents who were asked to take the different types of exams (alone and stratified by secondary variables) were examined using bootstrapping proportion comparison tests. Similarly, comparisons between the time intervals between having time to perform an examination and the delivery of its result, according to specific examination and secondary variables, were performed using a bootstrapping median comparison test, applying the percentile method for differences [32]. The association between secondary and primary qualitative variables was analyzed using Chi-square or Fisher's exact test, as appropriate. All analyses were performed using R (version 4.3.1) and Microsoft Excel software, considering 95% confidence (2.5 and 97.5 percentiles, Bootstrap) and a significance of 0.05.

Ethics

The study was approved by the ethical-scientific committee of the Faculty of Medicine, Universidad del Desarrollo, Clínica Alemana, Chile (Memorandum number 2021-67, July 26, 2021).

RESULTS

A sample size of 263 people was achieved, with men and women between 29 and 83 years old at the time of the survey.

Sociodemographic characteristics and healthcare

Of the 263 respondents, 260 reported being female (98.86%), with only one male respondent (0.38%; two did not respond). The sample showed a higher proportion between 50 and 69 years (49.05%), with 13.31% ($n = 35$) of respondents in the under-40 age bracket, similar to cancer prevalence data in Chile [33]. Regarding residence, 49.81% ($n = 131$) resided in the capital city (Metropolitan Region), similar to the national distribution [34]. In agreement with national data [35], higher education was the most frequent at 55.13%, followed by secondary education (37.64%). On the other hand, income had a 5% trimmed mean of \$1 125 098 CLP, with quintiles at the \$400 000 CLP, \$600 000 CLP, \$1 000 000 CLP, and \$2 000 000 CLP thresholds, respectively. Finally, similar to country statistics [35], 71.1% ($n = 187$) belonged to the public healthcare system, and 31.94% ($n = 84$) reported having complementary health insurance (Table 1). The percentage of participants with complementary health insurance from the private system was higher than those from the public system (61.84% versus 19.79%, $p < 0.05$).

Requested exams

Among the nine requested tests, the most frequent were biopsy and tumor marker tests, with 99.62% ($n = 262$; 95% CI: 98.86% to 100%) and 80.23% ($n = 211$; 95% CI: 75.29% to 84.79%), respectively. In contrast, the least requested tests were positron emission tomography, abdomen-pelvis ultrasound, and chest radiography (24% for the former and approximately 55% for the latter two), except for positron emission tomography (23.95% of requests). Imaging tests were requested in more than 50% of respondents, with chest computed tomography (78.71%; 95% CI: 73.76% to 83.65%) and bone scintigraphy (72.24%; 95% CI: 66.54% to 77.57%) being the most frequent.

Biopsy requests were significantly more frequent ($p < 0.05$) than the other examinations, and the same was observed for positron emission tomography. Likewise, blood tests and chest computed tomography differed significantly from abdominal ultrasound, abdomen-pelvis computed tomography, magnetic resonance imaging, and chest radiography. In contrast, abdominal ultrasound differed from scintigram and magnetic resonance scintigram ($p < 0.05$) (Table 2). For the total number of respondents, the median number of examinations requested was six examinations (Q1: 4, Q3: 8), with a mean of 5.87 examinations (SD: 2.24) (Table 3). 12.17% of respondents (95% CI: 8.37% to 16.35%) requested all examinations, and 3.8% ($n = 10$; 95% CI: 1.52% to 6.08%) only had one examination (biopsy) (Table 2).

When stratified by sociodemographic characteristics, access to healthcare, and cancer stage, no statistically significant differences were observed in the percentage of patients

Table 1. Sociodemographic characteristics of participants with breast cancer in the Chilean healthcare system [29].

Variable	N	%
Sex		
Male	1	0.38%
Female	260	98.86%
Unknown	2	0.76%
Age¹		
29 to 39 years old	35	13.31%
40 to 49 years old	83	31.56%
50 to 69 years old	129	49.05%
70 to 83 years old	12	4.56%
Unknown	4	1.52%
Area of residence		
Metropolitan region	131	49.81%
Other regions of Chile	130	49.43%
Unknown	2	0.76%
Monthly income²		
I	45	17.11%
II	52	19.77%
III	52	19.77%
IV	54	20.53%
V	55	20.91%
Unknown	5	1.90%
Educational level		
Elementary	14	5.32%
High school	99	37.64%
Higher	145	55.13%
Unknown ⁴	5	1.90%
Health insurance³		
Public	187	71.10%
Private	76	28.90%
Complementary health insurance⁵		
Does not have	172	65.70%
Does have	84	31.94%
Unknown	7	2.66%

Notes: ¹Age (mean: 51.7; standard deviation: 10.5; minimum. 29; max. 83; Q1:44; median: 51; Q3: 60; with 0.05 significance the normality hypothesis is rejected). ²Monthly income (mean: 1 327 254; 5% trimmed mean: 1 125 098; SD: 1 548 436; minimum 36 000; maximum. 15 000 000; Q1: 450 00; median: 800 000; Q3: 1 700 000; with 0.05 significance the normality hypothesis is rejected). Quintiles of income. I: [36 000 to 400 000); II: [400 000 to 600 000); III: [600 000 to 1 000 000); IV: [1 000 000 to 2 000 000) and V: 2 000 000 or more. ³Public includes the National Health Fund in all its sections and the Armed Forces. ⁴Unknown educational level includes respondents who reported having attended differential education. ⁵37 respondents with complementary insurance in the public system (versus 144 without insurance and six who do not know) and 47 respondents with complementary insurance in the private system (versus 28 without insurance and one who does not know). Source: Prepared by the authors.

requested to undergo all the tests by specific groups. In descriptive terms, the difference by diagnostic stage stands out, with those in the late stage of the disease (III to IV) being the most frequently requested to have all the tests (18.2% versus 9.6%) (Figure 1).

According to the report, the most frequent combination of requested tests was biopsy plus blood tests plus imaging (specifically, chest X-ray, chest computed axial tomography, abdominal ultrasound, abdomen-pelvis computed

axial tomography, bone scintigraphy, and magnetic resonance imaging) (Table 3), which was specifically requested by 12.17% (n = 32) of the participants.

Days between exam performance and results

The days between performance/result ranged from one day to one year (365 days) for the various examinations. Except for bone scintigraphy and biopsy, the median days to results were seven days for the other examinations, with interquartile ranges between three and 20 days. Specifically, the median days to result for the bone scintigram was 9.5 days (Q1: 5.5 to Q3: 20) and 15 days (Q1: 10 to Q3: 30) for the biopsy. The median number of elapsed days differed significantly between biopsy and other examinations (Table 2). When stratifying by secondary variables, the median number of days between performance/result ranged from 17 to 27.5 days according to specific groups: people between 40 and 49 years of age, residents of other regions, quintile I of monthly income, middle education, public healthcare system, without complementary health insurance and in late-stage of the disease presented the highest median number of days between performance/result for biopsy. In no case did the 75% percentile of the sample exceed 45 days of waiting time (Figure 2).

The perceived tests with the longest delay were biopsy (26.62%, 95% CI: 21.29 to 31.94), bone scintigram (21.29%, 95% CI: 16.35 to 26.24), and magnetic resonance imaging (10.65%, 95% CI: 7.22 to 14.45) (Table 2). After stratifying by sociodemographic characteristics, health insurance, complementary health insurance, and staging, biopsy, and scintigraphy remained in the first place (Table 3).

Disease staging

The most frequently requested tests were analyzed according to the stage of diagnosis. People with stage I and II diagnoses reported a median of 6 examinations. On the other hand, the most frequent combination for these stages was eight tests, specifically: biopsy, chest X-ray, chest CT scan, ultrasound, bone scintigraphy, abdomen-pelvis CT scan, MRI, and blood tests. A median of seven tests were requested from people in stages III and IV, with the most frequent combination being the tests mentioned earlier. In addition, it is noteworthy that in both cases, the examinations were requested from more than 50% of the people in each stage. For both cases, the test perceived with the longest delay between performance/result was biopsy (Table 3), being also the most requested test in stages I to II (100%) and III to IV (98.9%; 95% CI: 96.6 to 100). In more than 80% of the patients diagnosed in stages III and IV, the request for computed axial tomography of the thorax and bone scintigraphy stands out, a situation that differs for stages I and II where we note that, together with the biopsy, blood tests are the only ones performed in more than 80% of those surveyed (Table 4).

Some differences were descriptively observed between the percentage of respondents who claimed to be in stage III

Table 2. Requested diagnostic tests and days between the request and delivery time for each test [29].

	Test request ¹		Days between performance and delivery of results ^a					Perceived delay ^b	
	Yes	No	Unknown	n (%) ^a	Mean (SD)	Q1 - Median - Q3	Maximum		
Biopsy	n	262	1	0	249 (95%)	23.24 (24.39)	10 - 15 - 30	180	1°
	% (95% CI)	99.62% (98.86% to 100.00%)	0.38% (0.00% to 1.14%)	0.00%					
Blood test	n	211	40	12	176 (83.4%)	14.98 (22.40)	3 - 7 - 20	210	5°
	% (95% CI)	80.23% (75.29% to 84.79%)	15.21% (11.03% to 19.39%)	4.56% (2.28% to 7.22%)					
Chest CT	n	207	53	b	184 (88.9%)	16.33 (30.86)	4 - 7 - 15	230	6°
	% (95% CI)	78.71% (73.76% to 83.65%)	20.15% (15.59% to 25.10%)	1.14% (0.00% to 2.66%)					
Abdominal and pelvic US	n	145	117	1	126 (86.9%)	12.39 (22.1)	3 - 7 - 12	200	9°
	% (95% CI)	55.13% (49.05% to 61.22%)	44.49% (38.40% to 50.57%)	0.38% (0.00% to 1.14%)					
Abdominal and pelvic CT	n	164	93	6	163 (99.4%)	16.17 (29.33)	4 - 7 - 20	230	7°
	% (95% CI)	62.36% (56.27% to 68.44%)	35.36% (29.66% to 41.06%)	2.28% (0.76% to 4.18%)					
Bone scintigram	n	190	70	b	172 (90.5%)	19.31 (36.77)	5.5 - 9.5 - 20	365	2°
	% (95% CI)	72.24% (66.54% to 77.57%)	26.62% (21.29% to 31.94%)	1.14% (0.00% to 2.66%)					
MRI	n	155	100	8	140 (90.3%)	16.66 (24.63)	5 - 7 - 14	210	3°
	% (95% CI)	58.94% (52.85% to 65.02%)	38.02% (32.32% to 44.11%)	3.04% (1.14% to 5.32%)					
Chest X-ray	n	146	116	1	134 (91.8%)	11.85 (19.67)	4 - 7 - 14	200	8°
	% (95% CI)	55.51% (49.43% to 61.60%)	44.11% (38.02% to 50.19%)	0.38% (0.00% to 1.14%)					
PET-scan	n	63	163	37	55 (87.3%)	12.64 (13.96)	5 - 7 - 15	80	4°
	% (95% CI)	23.95% (19.01% to 29.28%)	61.98% (55.89% to 68.06%)	14.07% (9.89% to 18.25%)					

CT: computed tomography. MRI: magnetic resonance imaging. PET-scan: Positron-emission tomography scan. US: ultrasound.

^aOnly those who requested the corresponding exam and reported a time in days between the time of request and the time of delivery of the exam were considered for the estimation of descriptive statistics (n: number of respondents responding; %: percentage of the total who were requested the exam) for all types of exams analyzed with P value < 0.001 of the Kolmogorov-Smirnov normality test and Lilliefors correction for the days between the time of request and delivery of the exams.

^bPerceived delay: ranking generated based on the question "From the list of tests presented below, select the one you consider had the longest delay for delivery of results".

Notes: ¹ 3.80% of the respondents were asked for only one exam, 6.46% for two, 7.22% for three, 70.35% for 4 to 8, and 12.17% for all exams.

Notes: Blood tests for tumoral markers (HER2, Ki67), PET, and CT of the abdomen and pelvis. Data was obtained from respondents who live or have lived the experience of having breast cancer in the Chilean healthcare system.

Source: Prepared by the authors.

Table 3. Amount of requested examinations [29]

		Amount of examinations ¹ (Min., Q1, Median, Q3, Max.)	Combination of exams requested in higher proportion ²	Examinations perceived as most delayed ³	Late stage ⁴ (III to IV)
Sex	Male	5 - 5 - 5 - 5 - 5	[c1] [c2] Bx, Rx, CTc, US, CTap	Biopsy	0.00%
	Female	1 - 4 - 6 - 8 - 9	All	Biopsy	33.46%
	Unknown	6 - 6 - 7 - 8 - 8	Bx, Rx, CTc, US, BS, BT	BS	50.00%
Age	29 to 40 years old	3 - 5 - 6 - 8 - 9	All	Biopsy	34.29%
	40 to 49 years old	1 - 4 - 6 - 7 - 9	Bx, Rx, CTc, US, BS, CTap, MRI, BT	BS	32.53%
	50 to 69 years old	1 - 4 - 6 - 8 - 9	Bx, Rx, CTc, US, BS, CTap, MRI, BT	Biopsy	35.66%
	70 to 83 years old	2 - 4 - 7 - 8,5 - 9	All	Biopsy	8.33%
	Unknown	2 - 4 - 7 - 8,5 - 9	-	Biopsy	50.00%
Area of residence	Metropolitan region	1 - 4 - 6 - 8 - 9	Bx, Rx, CTc, US, BS, CTap, MRI, BT	Biopsy	34.35%
	Other	1 - 4 - 6 - 8 - 9	All	BS	32.31%
	Unknown	6 - 6 - 7 - 8 - 8	-	BS	50.00%
Net monthly income by quintiles	I	1 - 3 - 6 - 8 - 9	All	Biopsy	26.67%
	II	1 - 5 - 7 - 8 - 9	Bx, Rx, CTc, US, BS, CTap, MRI, BT	BS	51.92%
	III	1 - 4,5 - 6 - 8 - 9	Bx, Rx, CTc, US, BS, CTap, MRI, BT	BS	36.54%
	IV	1 - 5 - 6 - 7 - 9	Bx, Rx, CTc, US, BS, CTap, MRI, BT	Biopsy	27.78%
	V	1 - 4 - 6 - 8 - 9	All	Biopsy	25.45%
	Unknown	4 - 4 - 5 - 9 - 9	All	Biopsy	20.00%
Educational level	Basic	1 - 4 - 6 - 7 - 9	Bx, Rx, CTc, US, BS, CTap, MRI, BT	CTc	42.86%
	High school	1 - 4 - 6 - 8 - 9	All	Biopsy	39.39%
	Higher education	1 - 5 - 6 - 8 - 9	Bx, Rx, CTc, US, BS, CTap, MRI, BT	Biopsy	27.59%
	Unknown	2 - 3 - 6 - 7 - 8	-	Biopsy	60.00%
Health insurance	Public	1 - 4 - 6 - 8 - 9	Bx, Rx, CTc, US, BS, CTap, MRI, BT	Biopsy	34.22%
	Private	1 - 5 - 7 - 8 - 9	All	Biopsy	31.58%
Complementary health insurance	Does not have	1 - 4 - 6 - 8 - 9	Bx,Rx, CTc, US, BS, CTap, MRI, BT	Biopsy	35.47%
	Does have	2 - 5 - 7 - 8 - 9	All	Biopsy	27.38%
	Unknown	3 - 5 - 7 - 8 - 9	-	Biopsy	57.14%
Diagnostic stage	I to II	1 - 4 - 6 - 7 - 9	Bx, Rx, CTc, US, BS, CTap, MRI, BT	Biopsy	-
	III to IV	1 - 5 - 7 - 8 - 9	All	Biopsy	-
	Unknown	1 - 2 - 4 - 7 - 9	Bx	Biopsy	-

BS: bone scintigram. BT., blood tests. Bx: biopsy.CI: confidence interval. CT: computed axial tomography. CTap: Abdominal and pelvic computed axial tomography. CTc: computed axial tomography of the chest. MRI: magnetic resonance imaging. Rx: chest radiograph. US: ultrasound.
 Notes: ¹Descriptive measures, five-number summary, of the number of tests requested from each respondent, stratified according to sociodemographic characteristics and stage of diagnosis. ²According to sociodemographic characteristics and stage of diagnosis, the combination of tests most frequently reported by the corresponding group is indicated. ³According to sociodemographic characteristics and stage of diagnosis, the most frequently reported tests as "delayed" by each group. ⁴Percentage of respondents who reported being in late stages (stage III or IV) at the time of diagnosis according to sociodemographic characteristics.
 Notes: Combination of most frequent examinations, most delayed examinations, staging of sociodemographic characteristics and stage of diagnosis.
 Source: Prepared by the authors.

or IV at the time of breast cancer diagnosis by sociodemographic variables. For example, 34.35% of the respondents in the Metropolitan Region claimed to be at this stage, while this percentage corresponded to 3.31% for the other regions (Table 3).


DISCUSSION

This research characterized the profile of requested tests for the diagnosis and staging of breast cancer in Chile. It analyzed the time intervals between days of performance/result for each requested test, the latter to identify possible delays. With this in consideration, differences were found in these indicators of healthcare performance and compliance with breast cancer guarantees in the plan of Explicit Health Guarantees defined by law in Chile, according to clinical variables and social determinants of health.

The results of the investigation revealed that the most frequently performed examination was a biopsy in 99.62% (n = 262; 95% CI: 98.86 to 100) of the participants. This result shows that biopsy in Chile is the test of choice for diagnostic confirmation under international [36] and national recommendations [28]. An interesting finding was the request for bone scintigraphy in 72.24% of the participants. This is given that, although bone metastasis in breast cancer is the most frequent [37], this test is not recommended for the diagnostic confirmation of asymptomatic stage I and II patients [28]. The number of requested examinations was also noted, with a median of six (Q1: 4, Q3: 8) and a mean of 5.87 examinations (SD 2.24).

These results show differences between the criteria established in the clinical guidelines [28] and the request for examinations mentioned by the participants. This is because the imaging tests reported by the participants are mainly

Figure 1. Percentage of respondents who were asked for all tests.




Data was consulted according to sociodemographic characteristics and stage of diagnosis. Chile, 2021. Source: Prepared by the authors based on the results of the study.

recommended in the clinical guidelines for stage III and IV patients. In addition, only 31% (n = 64) of the participants stated having a diagnosis in these stages. On the other hand, no significant differences were observed in the request for examinations by social determinants of health. However, when analyzing days between performance/result, a greater delay for biopsy was observed in persons between 40 and 49 years

of age, residents of regions outside the Metropolitan region, belonging to the poorest income quintile of the sample, having secondary education, attending the public healthcare system, without complementary health insurance, and being at a late stage of the disease. Considering the differences in mortality results present in the country between groups according to place of residence [26] and educational level [27], the request

Figure 2. Days between biopsy order and delivery of results according to sociodemographic characteristics and stage of diagnosis [29].



PET: positron emission tomography.

CT: computed axial tomography.

Source: Prepared by the authors based on the study results.

Table 4. Diagnostic tests requested according to staging and health prognosis [29].

	Public		Private		Total	
	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)
Stage I and II						
Biopsy	108	100% (-)	48	100% (-)	156	100% (-)
Blood test	87	80.6% (73.2% to 88.0%)	39	81.3% (45.6% to 69.1%)	126	80.8% (74.4% to 86.5%)
CTc	80	74.1% (65.7% to 82.4%)	39	81.3% (45.6% to 69.1%)	119	76.3% (69.2% to 82.7%)
Abdominal and pelvic US	55	50.9% (41.7% to 60.2%)	27	56.3% (41.7% to 70.8%)	82	52.6% (44.9% to 60.3%)
Abdominal and pelvic CT	61	56.5% (47.2% to 65.7%)	32	66.7% (54.2% to 79.2%)	93	59.6% (51.92% to 67.3%)
Bone scintigram	73	67.6% (47.2% to 65.7%)	30	62.5% (47.9% to 77.1%)	103	66.0% (58.3% to 73.1%)
Chest X-ray	56	51.9% (42.6% to 61.1%)	27	56.3% (41.7% to 70.8%)	83	53.2% (45.5% to 60.9%)
PET	19	17.6% (11.1% to 25.0%)	11	22.9% (12.5% to 35.4%)	30	19.2% (13.5% to 25.6%)
Stages III and IV						
Biopsy	63	98.4% (95.3% to 100%)	24	100.0% (-)	87	98.9% (96.6% to 100%)
Blood test	51	79.7% (68.8% to 89.1%)	24	100.0% (-)	75	85.2% (77.3% to 92.1%)
CTc	55	85.9% (76.6% to 93.8%)	23	95.8% (87.5% to 100%)	78	88.6% (81.8% to 94.3%)
Abdominal and pelvic US	39	60.9% (48.4% to 73.4%)	18	75.0% (58.3% to 91.7%)	57	64.8% (54.6% to 75.0%)
Abdominal and pelvic CT	41	64.1% (51.6% to 75.0%)	21	87.5% (75.0% to 100%)	62	70.5% (61.4% to 79.6%)
Bone scintigram	52	81.3% (71.9% to 90.6%)	24	100.0% (-)	76	86.4% (78.4% to 93.2%)
Chest X-ray	39	60.9% (48.4% to 73.4%)	17	70.8% (50.0% to 87.5%)	56	63.6% (53.4% to 73.9%)
PET	19	29.7% (18.5% to 40.6%)	8	33.3% (16.7% to 54.2%)	27	30.7% (21.6% to 40.9%)

CI: confidence interval. CT: computed axial tomography. HER2: estrogen receptor. Ki67: progesterone receptor. PET: positron emission tomography. US: ultrasound.

Notes: Information obtained from participants who live or have lived with breast cancer in the Chilean healthcare system. Blood tests to evaluate tumor biomarkers (HER2, Ki67) and PET.

Source: Prepared by the authors.

for tests above the recommendations and the longer interval of days between biopsy performance/results could have an impact on delays in diagnosis and initiation of treatment [5–9].

This research has both strengths and limitations. As a strength, this unprecedented and exploratory study in Chile recognizes the experience and voice of breast cancer patients as a primary source of information. It is also the first study in Chile and Latin America that analyzes examinations as a fundamental part of the diagnostic and staging processes. This knowledge is useful for improving diagnosis, staging, treatment times, and system performance [3,4]. This novel study in the country, involving qualitative and quantitative variables, recognizes that it has limitations associated with the possibility of making inferences about the population within the quantitative nature of the study. Specifically, the non-probabilistic sample generated may introduce biases and limitations to the validity of the hypothesis tests, as well as not being representative of

the adult population living with breast cancer in Chile. Given the breadth of the target population, confidentiality, and how participants were invited, it was not possible to have a list of people from which a selection of participants could be made. Consequently, it was not possible to construct a sampling frame. To compensate for this shortcoming, an attempt was made to describe in detail the participant recruitment process. With this in mind, the study design allows the generation of hypotheses for future research.

Also, confidence intervals and comparisons were performed with resampling methods [32], which may provide a more suitable approach for inference in non-probability samples. This technique helps to estimate confidence intervals and empirical distributions of statistics without requiring assumptions about the underlying distribution of the data. On the other hand, it is recognized that the design of the study, the cross-sectional nature of the data obtained through a survey that collects the

experience and perception of the respondents, does not allow for establishing causal relationships. In addition, there is a risk of bias in the self-administered questionnaire, which does not have validity and reliability analyses. Finally, it is recognized as a limitation of the study that the pandemic period may have influenced the information obtained from some of the participants, increasing the time of access to examinations and influencing the non-consultation even in the face of the need.

Likewise, future research could address the problem through medical records to avoid self-reporting biases and exclusion of certain population groups (such as those without the possibility of responding to a survey). Other alternatives are carrying out a study on a larger scale and budget that allows using probability samples or sectioning the research to address this issue in specific population groups. These specific groups can be detailed with more specific characteristics of health conditions or sociocultural characteristics of one or more countries. These studies can be extended to other Latin American countries, where increases in breast cancer prevalence have been observed.

CONCLUSIONS

This research seeks to provide new knowledge on breast cancer, focusing on the delays in diagnosis both locally and internationally, with special regard to diagnostic tests and staging necessary to initiate timely treatment. By analyzing our results in detail and considering the identified limitations and context, we aim to offer a clearer vision of this problem.

Addressing the delay in the diagnosis of breast cancer is an ethical and legal responsibility. It highlights preventable and modifiable differences in access to examinations that are fundamental for the effective and equitable management of this pathology in Chile.

In addition, this research will contribute to a better understanding of the inequities in access to breast cancer diagnostic and staging tests in Chile, according to various determinants. This is a key step to reduce diagnostic time and ensure more timely treatments [38].

Contributor roles CC: conceptualization, research, writing the original draft. MO: conceptualization, writing the original draft, supervision. BC, AO: conceptualization, writing, review, and editing.

Acknowledgments The authors express their gratitude to Patients, cancer patient organizations, and health institutions for their contribution in recruitment, the Doctoral Program in Science and Innovation in Medicine, Universidad del Desarrollo, and the Chilean Center for Cancer Prevention and Control (CECAN), ANID FONDAP 152220002 ANID Chile.

Conflictos de intereses The authors declare no conflicts of interest.

Funding Project funded by the Centro para la Prevención y Control del Cáncer de Chile (CECAN), ANID FONDAP 152220002 ANID Chile.

Language of submission Spanish.

Peer review and provenance Not commissioned. Externally peer-reviewed by three reviewers, double-blind.

REFERENCES

- Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell*. 2000;100: 57–70. [https://doi.org/10.1016/s0092-8674\(00\)81683-9](https://doi.org/10.1016/s0092-8674(00)81683-9)
- Łukasiewicz S, Czezelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. *Cancers (Basel)*. 2021;13. <https://doi.org/10.3390/cancers13174287>
- Barrios CH. Global challenges in breast cancer detection and treatment. *Breast*. 2022;62 Suppl 1: S3–S6. <https://doi.org/10.1016/j.breast.2022.02.003>
- Ginsburg O, Vanderpuye V, Beddoe AM, Bhoo-Pathy N, Bray F, Caduff C, et al. Women, power, and cancer: a Lancet Commission. *The Lancet*. 2023;402: 2113–2166. [https://doi.org/10.1016/S0140-6736\(23\)01701-4/ATTACHMENT/F58F0C2F-4EEC-4347-B2FA-82903FE0B7E1/MMC1.PDF](https://doi.org/10.1016/S0140-6736(23)01701-4/ATTACHMENT/F58F0C2F-4EEC-4347-B2FA-82903FE0B7E1/MMC1.PDF)
- Neal RD, Allgar VL. Sociodemographic factors and delays in the diagnosis of six cancers: analysis of data from the “National Survey of NHS Patients: Cancer.” *Br J Cancer*. 2005;92: 1971–5. <https://doi.org/10.1038/sj.bjc.6602623>
- Pocock B, Nash S, Klein L, El-Tamer M, Schnabel FR, Joseph KA. Disparities in time to definitive surgical treatment between black and white women diagnosed with ductal carcinoma in situ. *Am J Surg*. 2007;194: 521–3. <https://doi.org/10.1016/j.amjsurg.2007.06.015>
- Smith ER, Adams SA, Das IP, Bottai M, Fulton J, Hebert JR. Breast cancer survival among economically disadvantaged women: The influences of delayed diagnosis and treatment on mortality. *Cancer Epidemiology Biomarkers and Prevention*. 2008;17: 2882–2890. <https://doi.org/10.1158/1055-9965.EPI-08-0221/344157/P/breast-cancer-survival-among-economically>
- Gorin SS, Heck JE, Cheng B, Smith SJ. Delays in breast cancer diagnosis and treatment by racial/ethnic group. *Arch Intern Med*. 2006;166: 2244–52. <https://doi.org/10.1001/archinte.166.20.2244>
- Lund MJ, Brawley OP, Ward KC, Young JL, Gabram SSG, Eley JW. Parity and disparity in first course treatment of invasive breast cancer. *Breast Cancer Res Treat*. 2008;109: 545–557. <https://doi.org/10.1007/S10549-007-9675-8/TABLES/6>
- Anderson BO, Jakesz R. Breast cancer issues in developing countries: An overview of the Breast Health Global Initiative. *World J Surg*. 2008;32: 2578–2585. <https://doi.org/10.1007/S00268-007-9454-Z/TABLES/7>
- Unger-Saldaña K. Challenges to the early diagnosis and treatment of breast cancer in developing countries. *World J Clin Oncol*. 2014;5: 465–77. <https://doi.org/10.5306/wjco.v5.i3.465>
- McDaniel JT, Nuhu K, Ruiz J, Alorbi G. Social determinants of cancer incidence and mortality around the world: an ecological study. *Glob Health Promot*. 2019;26: 41–49. <https://doi.org/10.1177/1757975916686913>

13. Venkataramany BS, Sutton JM. Social Determinants of Health in Oncology: Towards a More Personalized and Equitable Delivery of Cancer Care. *Am J Clin Oncol*. 2022;45: 273–278. <https://doi.org/10.1097/COC.0000000000000914>
14. Alcaraz KI, Wiedt TL, Daniels EC, Yabroff KR, Guerra CE, Wender RC. Understanding and addressing social determinants to advance cancer health equity in the United States: A blueprint for practice, research, and policy. *CA Cancer J Clin*. 2020;70: 31–46. <https://doi.org/10.3322/caac.21586>
15. Cutler DM, Lleras-Muney A. National Poverty Center Policy Brief Education and Health. 2007. Available: http://www.npc.umich.edu/publications/policy_briefs/brief9/policy_brief9.pdf
16. Ingram RC, Scutchfield FD, Charnigo R, Riddell MC. Local public health system performance and community health outcomes. *Am J Prev Med*. 2012;42: 214–20. <https://doi.org/10.1016/j.amepre.2011.10.022>
17. Bleicher RJ. Timing and Delays in Breast Cancer Evaluation and Treatment. *Ann Surg Oncol*. 2018;25: 2829–2838. <https://doi.org/10.1245/S10434-018-6615-2/FIGURES/1>
18. Unger-Saldaña K, Infante-Castañeda C. Delay of medical care for symptomatic breast cancer: a literature review. *Salud Publica Mex*. 2009;51 Suppl 2: s270–85. <https://doi.org/10.1590/s0036-36342009000800018>
19. Ramirez AJ, Westcombe AM, Burgess CC, Sutton S, Littlejohns P, Richards MA. Factors predicting delayed presentation of symptomatic breast cancer: A systematic review. *Lancet*. 1999;353: 1127–31. [https://doi.org/10.1016/s0140-6736\(99\)02142-x](https://doi.org/10.1016/s0140-6736(99)02142-x)
20. Facione NC. Delay versus help seeking for breast cancer symptoms: A critical review of the literature on patient and provider delay. *Soc Sci Med*. 1993;36: 1521–34. [https://doi.org/10.1016/0277-9536\(93\)90340-a](https://doi.org/10.1016/0277-9536(93)90340-a)
21. In: Organización Mundial de la Salud. Cáncer de mama [Internet]. 12 Jul 2023. <https://www.who.int/es/news-room/fact-sheets/detail/breast-cancer>
22. Cazap E. Breast Cancer in Latin America: A Map of the Disease in the Region. *Am Soc Clin Oncol Educ Book*. 2018;38: 451–456. https://doi.org/10.1200/EDBK_201315
23. Azamjah N, Soltan-Zadeh Y, Zayeri F. Global Trend of Breast Cancer Mortality Rate: A 25-Year Study. *Asian Pac J Cancer Prev*. 2019;20: 2015–2020. <https://doi.org/10.31557/APJCP.2019.20.7.2015>
24. International Agency for Research on Cancer. Chile, GLOBOCAN 2020; <https://gco.iarc.fr/today/data/factsheets/populations/152-chile-fact-sheets.pdf>
25. Ministerio de Salud, Departamento de Epidemiología. Informe de Vigilancia de Cáncer Análisis de Mortalidad Década 2009-2018. Chile; 2020. http://epi.minsal.cl/wp-content/uploads/2021/05/Informe_Mortalidad_por_Cancer_2009_2018.pdf
26. Durán D, Monsalves MJ. Spatial autocorrelation of breast cancer mortality in the Metropolitan Region, Chile: an ecological study. *Medwave*. 2020;20: e7766. <https://doi.org/10.5867/medwave.2020.01.7766>
27. Herrera Riquelme CA, Kuhn-Barrientos L, Rosso Astorga R, Jiménez de la Jara J. Tendencia de la mortalidad por cáncer en Chile según diferencias por nivel educacional, 2000-2010. *Rev Panam Salud Publica*. 2015;37: 44–51.
28. Ministerio de Salud. Guías Clínicas Cáncer de Mama. Santiago: Minsal; 2015.
29. Ceballos-Morales A, Burgos-Portales D, Carrasco-Portiño M, Manríquez-Vidal C, Ceballos-Morales A, Burgos-Portales D. Caracterización del cáncer de mama de un servicio de salud pública del sur de Chile según edad, período 2005-2015. *Rev chil obstet ginecol*. 2021;86: 175–185. <https://doi.org/10.4067/S0717-75262021000200175>
30. Cabieses B, Obach A, Espinoza M, Rodríguez C. Identificando brechas en trayectorias terapéuticas de pacientes adultos con cáncer de mama y pulmón en Chile: develando desigualdades en la atención de patologías priorizadas. Resultados fase cualitativa. Universidad del Desarrollo. Facultad de Medicina. ICIM; 2022. Available: <http://hdl.handle.net/11447/6595>
31. American Cancer Society. In: Recomendaciones de la Sociedad Americana Contra El Cáncer para la detección temprana del Cáncer de seno | American Cancer Society [Internet]. Sep 2023. <https://www.cancer.org/es/cancer/tipos/cancer-de-seno/pruebas-de-deteccion-y-deteccion-temprana-del-cancer-de-seno/guias-de-la-sociedad-americana-contra-el-cancer-para-la-deteccion-temprana-del-cancer-de-seno.html>
32. Wood M. Bootstrapped Confidence Intervals as an Approach to Statistical Inference. *Org Res Methods*. 2005;8: 454–470. <https://doi.org/10.1177/1094428105280059>
33. Merino GF, Alfaro T, Petric M, Sánchez C, Labbé TP, Ríos JA. Caracterización de la incidencia del cáncer de mama en un servicio público de salud chileno en el período 2006-2015. *RECHOG*. 2022;87: 188–193. <https://doi.org/10.24875/RECHOG.22000015>
34. Chile BCNB del CN de. Reportes Estadísticos 2023 de Santiago. Bibl Cong Nac Chile. 2023; Available. https://www.bcn.cl/siit/reportescomunales/comunas_v.html?anno=2023&idcom=13101
35. In: Observatorio Social - Ministerio de Desarrollo Social y Familia [Internet]. 28 Sep 2023. <https://observatorio.ministeriodesarrollosocial.gob.cl/encuesta-casen-2022>
36. Jung I, Kim MJ, Moon HJ, Yoon JH, Kim EK. Ultrasonography-guided 14-gauge core biopsy of the breast: results of 7 years of experience. *Ultrasonography*. 2018;37: 55–62. <https://doi.org/10.14366/usg.17028>
37. Brook N, Brook E, Dharmarajan A, Dass CR, Chan A. Breast cancer bone metastases: pathogenesis and therapeutic targets. *Int J Biochem Cell Biol*. 2018;96: 63–78. <https://doi.org/10.1016/j.biocel.2018.01.003>
38. Lopes TCR, Gravena AAF, Demitto MO, Borghesan DHP, Dell'Agnolo CM, Brischiliari SCR, et al. Delay in Diagnosis and

Treatment of Breast Cancer among Women Attending a Reference Service in Brazil. *Asian Pac J Cancer Prev.* 2017;18:3017. <https://doi.org/10.22034/APJCP.2017.18.11.3017>

Diagnóstico y etapificación de cáncer de mama en Chile: estudio por encuesta no probabilística de III a IV frecuencia y tiempos

RESUMEN

INTRODUCCIÓN La progresión del cáncer de mama involucra mecanismos fisiológicos como metástasis. Los retrasos en diagnóstico y tratamiento aumentan el riesgo de mortalidad y se asocian a barreras de acceso a la salud. En Chile, el cáncer de mama es altamente prevalente y su diagnóstico temprano ha mejorado, aunque persisten disparidades en el proceso de enfermedad. Este estudio caracterizó exámenes de diagnóstico y etapificación, tiempos de espera y perfiles sociodemográficos para identificar demoras e inequidades en la atención.

MÉTODOS Estudio de encuesta. Utilizando una muestra no probabilística, se aplicó un cuestionario en plataforma encriptada previo consentimiento informado. En el instrumento se recogieron datos de exámenes solicitados, tiempos asociados, etapificación y características sociodemográficas. Estas variables fueron analizadas utilizando estadística descriptiva, test de asociación, intervalos de confianza y test de comparación utilizando *bootstrapping*.

RESULTADOS Se logró una muestra de 263 personas. Los exámenes más solicitados fueron biopsia (99,62%) y exámenes de sangre (80,23%). La mediana de exámenes solicitados fue de 6 (Q1:4, Q3:8), con media 5,87 (desviación estándar: 2,24). No se observaron diferencias significativas en el porcentaje de personas a quienes se solicitó la totalidad de exámenes según variables estudiadas. Los intervalos día-hora-resultado oscilaron entre 1 y 365 días. La mediana día-hora-resultado de la biopsia fue de 15 días (Q1:10, Q3:30). Las personas entre 40 y 49 años, no residentes de la capital, pertenecientes al quintil I de ingreso, con educación media, del sistema público de salud, con diagnóstico en etapa tardía presentaron mayores medianas de día-hora-resultado en biopsia. No hubo diferencia significativa en la cantidad de exámenes solicitados según etapificación (I a II y III a IV).

CONCLUSIONES La biopsia en Chile es el examen de elección para la confirmación diagnóstica en cáncer de mama. Otros exámenes son solicitados independientemente de la etapa del diagnóstico, existiendo una discordancia con las recomendaciones de la guía clínica. El pronóstico del cáncer es crucial, especialmente en países con mayores inequidades.



This work is licensed under a Creative Commons Attribution 4.0 International License.